Familial hyperlipidemia
MONDO:0001336An instance of hyperlipidemia (disease) that is caused by an inherited modification of the individual's genome.
Also known as: hyperlipemia, hyperlipidaemia, hereditary hyperlipidemia (disease), familial hyperlipemia, familial hyperlipoproteinemia
131 clinical trials for this condition and its sub-types, 8 tagged with Familial hyperlipidemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial hyperlipidemia
-
Familial hypercholesterolemia 58 trials · 94 incl. sub-types
5 sub-types
-
Hyperlipoproteinemia type 3 4 trials
-
Hyperlipoproteinemia type V 2 trials
-
Hyperlipidemia, combined, 2 0 trials
-
Hyperlipoproteinemia, type 1D 0 trials
-
Can an unapproved device change how we manage this condition?
Disease control Not yet recruitingThis trial tests a medical device that has not been approved or cleared by the U.S. FDA. Researchers want to learn whether the device is safe and whether it can help people with a specific condition. Participants receive the device as part of the study, and the team monitors thei…
Phase 4 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
New team approach aims to simplify care for heart and kidney health
Disease control Not yet recruitingThis study tests a 6-month program where patients work with a pharmacist and their primary care doctor to make shared decisions about medications and lifestyle. The goal is to see if this team-based approach improves heart and kidney health scores and medication adherence. The st…
Early phase 1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new RNA drug tame high blood fats?
Disease control Not yet recruitingThis trial tests whether EDP167, an experimental RNA drug, can safely lower triglycerides and other harmful fats in the blood of adults with mixed dyslipidemia. Participants receive one of three doses of EDP167 or a placebo as an injection every 12 weeks, alongside their usual st…
Phase 2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a monthly shot keep Kids' inherited high cholesterol in check for years?
Disease control Not yet recruitingThis trial is testing whether a monthly injection of lerodalcibep (Lerochol) can safely and effectively lower LDL cholesterol over three years in children and adolescents aged 6 to 17 with heterozygous familial hypercholesterolemia (HeFH), an inherited condition causing very high…
Phase 3 • Sponsor: LIB Therapeutics LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a purified fish oil calm the 'hot' plaques that trigger heart attacks?
Disease control Not yet recruitingThis trial tests whether icosapent ethyl, a purified form of fish oil, can stabilize high-risk coronary plaques in people with heart disease. Participants have plaques that narrow a major heart artery by 30–70% and show at least one high-risk feature on a CT scan. Half will take …
Phase 4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo pill aims to supercharge cholesterol lowering
Disease control Not yet recruitingThis Phase 3 trial tests whether a new combination pill containing laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone. About 200 adults with high cholesterol and a history of heart disease or high risk will take either the combo or a placebo plus …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New shot could help teens with rare, severe high cholesterol
Disease control Not yet recruitingThis study tests a new drug called zodasiran in 12 teens aged 12 to 17 with homozygous familial hypercholesterolemia, a rare genetic condition causing very high cholesterol. The drug is given as a shot under the skin. The main goal is to see if it safely lowers bad cholesterol af…
Phase 3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Gene-Editing shot takes aim at inherited high cholesterol
Disease control Not yet recruitingThis early study tests a new injection called ART002g1 in 24 adults with a genetic form of high cholesterol (HeFH). The injection uses gene editing to lower a protein that raises cholesterol levels. The main goal is to check safety and how well the drug works at reducing choleste…
Early phase 1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame inherited high cholesterol
Disease control Not yet recruitingThis Phase III trial tests QLC7401, a new RNA-based drug, in 120 adults with heterozygous familial hypercholesterolemia (a genetic condition causing very high cholesterol). Participants already on cholesterol medication will receive either QLC7401 or a placebo injection. The stud…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cholesterol drug QLC7401 enters final testing phase
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called QLC7401 in about 780 adults with high cholesterol that remains high despite standard therapy. Participants will receive either QLC7401 or a placebo, added to their current cholesterol medications. The main goal is to see if QLC7401 can s…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New Omega-3 pill could boost heart health better than standard fish oil
Disease control Not yet recruitingThis study tests whether a new omega-3 supplement called Ruby-O, made from phospholipids, raises omega-3 levels in the blood more effectively than standard omega-3 supplements. About 105 adults with mixed dyslipidemia (abnormal blood fats) who are already on statin therapy will t…
Sponsor: Fundación del Caribe para la Investigación Biomédica • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New shot could help when statins Aren't enough for high cholesterol
Disease control Not yet recruitingThis study tests a new injectable drug called DNV001 in about 120 adults with high cholesterol that isn't well controlled by statins. Participants will receive different doses of the drug or a placebo as a shot under the skin, while continuing their usual statin pills. The main g…
Phase 2 • Sponsor: Hangzhou Dinovate Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cholesterol drug candidate enters early human testing
Disease control Not yet recruitingThis early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. …
Phase 1 • Sponsor: Addpharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Which contact method best warns families of hidden cholesterol danger?
Knowledge-focused Not yet recruitingThis study compares two approaches to notify relatives of people diagnosed with familial hypercholesterolemia (FH), a genetic condition causing very high cholesterol. One method lets patients share information themselves; the other has the study team contact relatives directly. R…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Are cholesterol patients getting the right care? new study aims to find out
Knowledge-focused Not yet recruitingThis study will follow about 2,500 adults in Italy who have high cholesterol and are at high risk for heart problems. Researchers want to see if their current treatments match official guidelines and how well their cholesterol is controlled over one year. The goal is to find gaps…
Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Cholesterol drug showdown: which one do patients actually take?
Knowledge-focused Not yet recruitingThis study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treat…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Gum disease linked to heart risk marker in new study
Knowledge-focused Not yet recruitingThis study compares levels of oxidized LDL (a type of 'bad' cholesterol linked to heart disease) in the gum fluid of people with advanced gum disease versus those with healthy gums. Researchers aim to better understand the connection between gum inflammation and heart health. The…
Sponsor: shaimaa hamdy • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:15 UTC